Study of Eculizumab in Patients with GMG

ID Number 08-1294

Principal Investigator(s)
Mark A Sivak

Department(s) or Division(s)


The purpose of this study is to evaluate the safety of the drug eculizumab in a randomized, double-blind, placebo-controlled cross-over trial of patients with generalized Myasthenia Gravis (MG) who have not responded to other MG treatments.

Contact Information
Joan Bratton
(212) 659-5643

Recruiting Patients: Yes